Copeptin decrease from admission to discharge has favorable prognostic value for 90-day events in patients admitted with dyspnea

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 10, 2014, Pages 1457-1464

  Vetronea, Francesco ^a   Santarelli, Simona ^a   Russo, Veronica ^a   Lalle, Irene ^a   De Berardinis, Benedetta ^a   Magrini, Laura ^a   Di Stasioa, Enrico ^b   Salerno, Gerardo ^a   Cardelli, Patrizia ^a   Piccoli, Antonio ^c   Codognotto, Marta ^c   Maria Mion, Monica ^c   Plebani, Mario ^c   Vettore, Gianna ^c   Castello, Luigi Mario ^c   Carlo Avanzi, Gian ^c   Di Somma, Salvatore ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Acute heart failure; Copeptin; Dyspnea; Emergency department; Prognosis; Serial assessment

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; COPEPTIN; GLYCOPEPTIDE;

ACUTE HEART FAILURE; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DEATH; DISEASE EXACERBATION; DYSPNEA; EMERGENCY WARD; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OBSERVATIONAL STUDY; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; BIOASSAY; BLOOD; EMERGENCY HEALTH SERVICE; STATISTICS AND NUMERICAL DATA;

AGED; DYSPNEA; EMERGENCY SERVICE, HOSPITAL; ENDPOINT DETERMINATION; FEMALE; GLYCOPEPTIDES; HUMANS; MALE; PATIENT ADMISSION; PATIENT DISCHARGE; PATIENT READMISSION; PROGNOSIS;

EID: 84919787238     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0207     Document Type: Article

References (30)

1. Parrinello G, Paterna S, Di Pasquale P, Torres D, Fatta A, Mezzero M, et al. The usefulness of bioelectrical impedance analysis in differentiating dyspnea due to decompensated heart failure. J Card Fail 2008;14:676-86.
2. Gori CS, Magrini L, Travaglino F, Di Somma S. Role of biomarkers in patients with dyspnea. Eur Rev Med Pharmacol Sci 2011;15:229-40.
3. Potocki M, Breidthardt T, Mueller A, Reichlin T, Socrates T, Arenja N, et al. Copeptin and risk stratification in patients with acute dyspnea. Crit Care 2010;14:R213.
4. Lee DS, Schull MJ, Alter DA, Austin PC, Laupacis A, Chong A, et al. Early deaths in heart failure patients discharged from emergency department: a population based analysis. Circ Heart Fail 2010;3:228-35.
5. Eurlings LW, Sanders-van Wijk S, van Kimmenade R, Osinski A, van Helmond L, Vallinga M, et al. Multimarker strategy for short term risk assessment in patients with dyspnea in the emergency department. J Am Coll Cardiol 2012;60:1668-77.
6. Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013;168:2186-94.
7. Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O, et al. Short term mortality risk in emergency department acute heart failure. Acad Emerg Med 2011;18:947-58.
8. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, Mueller T. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 2010;43:714-9.
9. Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med 2012;10:7.
10. Yalta K, Yalta T, Sivri N, Yetkin E. Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 2013;167:1750-9.
11. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 2005;95:8B-13B.
12. Birnbaumer M. Vasopressin receptors. Trends Endocrinol Metab 2000;11:406-10.
13. Giannopoulos G, Deftereos S, Panagopoulou V, Kossyvakis C, Kaoukis A, Bouras G, et al. Copeptin as a biomarker in cardiac disease. Curr Top Med Chem 2013;13:231-40.
14. Katan M, Christ Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010;140:w13101.
15. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol 2010;56:1712-9.
16. Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145-52.
17. Urwyler SA, Schuetz P, Fluri F, Morgenthaler NG, Zweifel C, Bergmann A, et al. Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke 2010;41:1564-7.
18. Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010;121:2102-8.
19. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131:1058-67.
20. Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ- Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219-26.
21. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Eur J Heart Fail 2012;14:803-69.
22. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009;116:257-63.
23. Stoiser B, Mörtl D, Hülsmann M, Berger R, Struck J, Morgenthaler NG, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006;36:771-8.
24. Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) Study. Circ Heart Fail 2011;4:613-20.
25. Alehagen U, Dahlström U, Rehfeld JF, Goetze JP. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. J Am Med Assoc 2011;305:2088-95.
26. Balling L, Kistorp C, Schou M, Egstrup M, Gustafsson I, Goetze JP, et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail 2012;18:351-8.
27. Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009;94:123-9.
28. Fenske W, Quinkler M, Lorenz D, Zopf K, Haagen U, Papassotiriou J, et al. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome. Revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab 2011;96:1506-15.
29. Miller WL, Hartman KA, Grill DE, Struck J, Bergmann A, Jaffe AS. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 2012;98:389-94.
30. Di Somma S, Magrini L, Pittoni V, Marino R, Mastrantuono A, Ferri E, et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Crit Care 2010;14:R116.